Hostname: page-component-848d4c4894-r5zm4 Total loading time: 0 Render date: 2024-06-19T23:12:06.977Z Has data issue: false hasContentIssue false
  • English
  • Français

Course of the Metabolic Syndrome (Mets) in a First Episode Psychosis Sample

Published online by Cambridge University Press:  01 September 2022

E. Garcia De Jalon ,
L. Aranguren ,
A. Fernandez Falces ,
A. Aquerreta Unzue  and
N. Pereda
E. Garcia De Jalon
Affiliation:
SERVICIO NAVARRO DE SALUD, Programa De Primeros Episodios, PAMPLONA, Spain
L. Aranguren*
Affiliation:
SERVICIO NAVARRO DE SALUD, Programa De Primeros Episodios, PAMPLONA, Spain
A. Fernandez Falces
Affiliation:
SERVICIO NAVARRO DE SALUD, Programa De Primeros Episodios, PAMPLONA, Spain
A. Aquerreta Unzue
Affiliation:
SERVICIO NAVARRO DE SALUD, Programa De Primeros Episodios, PAMPLONA, Spain
N. Pereda
Affiliation:
SERVICIO NAVARRO DE SALUD, Programa De Primeros Episodios, PAMPLONA, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

There is evidence that metabolic syndrome (MetS) is common in chronic psychosis but also exists in the early stages.

Objectives

To study the prevalence and course of MetS over a period of 2 year after a first episode psychosis. To determine whether there may be differences in its prevalence according to the type of antipsychotic used over two years.

Methods

A sample of 300 patients participate in the PEPsNa Early Intervention Programme. SMet was determined at baseline and at 6, 12, 18 and 24 months. The type of antipsychotic used at each assessment moment is collected (none, aripiprazole, paliperidone, others). Adult Treatment Panel III (ATP III) criteria were used to define MetS.

Results

The prevalence of MetS at baseline is 4.44% and increases to 7.96% at 6 months, 10.1% at 12 months, 8.62% at 18 months and 9.01% at 24 months. The prevalence of MetS increases at 6 (p<0.021) and 12 months (p<0.003) compared to baseline and then remains stable. Only at 6 months assessment there are significant differences (F-Ficher p<0.022) in the presence of MetS (15.8%) in the paliperidone group treatment (oral or LAI).

Conclusions

Metabolic syndrome (MetS) exists from the early stages of psychosis and increases in the first 6-12 months and remains stable thereafter. The type of antipsychotic treatment only seems to have an influence at 6 months, with no differences at other follow-up times.

Disclosure

No significant relationships.

Keywords

First-episode psychosismetabolic syndromeantipsychotic treament
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S247 - S248
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.